4
Changes in Ownership
Atara Biotherapeutics, Inc. Filed Acc 0001209191-18-030722
EVP, R&D & Chief Scientific Of sold 25,775 shares at an average $45.30 ($1,167,480)
- EVP, R&D & Chief Scientific Of acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-05-15 | Option exercise | +25,000 | $11.00 | $275,000 | 357,905 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-05-15 | Sale | −6,885 | $44.44 | $305,969 | 351,020 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-05-15 | Sale | −9,638 | $45.21 | $435,734 | 341,382 | D |
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-05-15 | Sale | −9,252 | $46.02 | $425,777 | 332,130 | D |
| Derivatives | |||||||
| Haqq Christopher EVP, R&D & Chief Scientific Of | 2018-05-15 | Option exercise · Employee Stock Option (Right to Buy) | −25,000 | 25,000 | D | ||
| Open-market sales · 25,775 sh · avg $45.30 · $1,167,480 | |||||||
Loading xslF345X03/doc4.xml…